Trialjectory Inc. and Precipio, Inc. Partner to Provide Cancer Patients with First-Of-Its-Kind Diagnostic and Clinical Trial-Matching Service
January 28, 2020 at 09:00 am EST
Share
Trialjectory Inc. announced that the Company has launched a new partnership with specialty cancer diagnostics company Precipio, Inc. to provide cancer patients worldwide with a first-of-its-kind diagnostic and clinical trial-matching service that assists doctors in providing the best possible treatment for their patients. With this partnership, Precipio's comprehensive diagnostic result reports will now include a personalized list of relevant clinical trials matched to the patient based on the trials' eligibility requirements, which are generated by TrialJectory's AI-based clinical trial-matching platform. The platform uses patient clinical information to facilitate the clinical trial search, matching and enrollment by patients and their physicians. If patients decide to further explore one or more of the matched trials, TrialJectory facilitates, on behalf of the patient, all communication with the clinical trial lead, including document collection, appointment scheduling and more.
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Companyâs technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Companyâs laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.